Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rapid Micro BiosystemsRPID -5.42%64 3-Year EBITDA Growth Rate is 12.40% as of Jun. 2026, which is 377% above its 10-year median of 2.60. GuruFocus rates RPID with a GF Score™ of 64/100 and a GF Value™ of $1.91 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 691 Medical Devices & Instruments companies, Rapid Micro Biosystems ranks better than 54.56% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 12.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 8.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Rapid Micro Biosystems was 24.40% per year. The lowest was -31.40% per year. And the median was 2.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Rapid Micro Biosystems 3-Year EBITDA Growth Rate Related Terms
RPID vs CVRX, ZOMDF, SERA: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Rapid Micro Biosystems's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapid Micro Biosystems 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Rapid Micro Biosystems's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Rapid Micro Biosystems's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 12.40% mean?
Rapid Micro Biosystems (RPID) has a 3-Year EBITDA Growth Rate of 12.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Rapid Micro Biosystems and its competitors. This is 377% above median its historical median of 2.60. According to the industry distribution chart, Rapid Micro Biosystems ranks #314 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 45.4%.
Is Rapid Micro Biosystems' 3-Year EBITDA Growth Rate too high?
Rapid Micro Biosystems' current 3-Year EBITDA Growth Rate of 12.40% is 377% above median its 10-year median of 2.60. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.70. Rapid Micro Biosystems' value of 12.40% is 61% above this industry median. Based on the distribution chart, Rapid Micro Biosystems ranks #314 out of 691 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Rapid Micro Biosystems has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rapid Micro Biosystems' 3-Year EBITDA Growth Rate compare to CVRX and ZOMDF?
According to the Medical Devices & Instruments industry distribution chart, Rapid Micro Biosystems ranks #314 out of 691 companies for 3-Year EBITDA Growth Rate. This puts Rapid Micro Biosystems in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.70. Rapid Micro Biosystems' value of 12.40% is 61% above this benchmark. While the company's 10-year median is 2.60 vs. the industry median of 7.70, Rapid Micro Biosystems has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.70, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rapid Micro Biosystems's current 3-Year EBITDA Growth Rate of 12.40% is 61% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Rapid Micro Biosystems and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rapid Micro Biosystems's current 3-Year EBITDA Growth Rate is 12.40%, which is 377% above median its own 10-year median of 2.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Micro Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Rapid Micro Biosystems (RPID) is currently considered Possible Value Trap. The stock's GF Value™ is $1.91, compared to a current price of $1.31 — trading 31.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 12.40%, which is 377% above median its 10-year median of 2.60 and 61% above the Medical Devices & Instruments industry median of 7.70. Rapid Micro Biosystems' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Rapid Micro Biosystems (RPID), the current 3-Year EBITDA Growth Rate is 12.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rapid Micro Biosystems (RPID) Overvalued in 2026?
Based on GuruFocus' analysis, Rapid Micro Biosystems stock appears to be undervalued.
The current stock price of $1.31 is trading 31.4% below its estimated GF Value™ of $1.91.
GuruFocus considers Rapid Micro Biosystems to be Possible Value Trap.
Key valuation signals for RPID:
3-Year EBITDA Growth Rate: 12.40% (377% above median its 10-year median of 2.60)
GF Value™: $1.91 vs. price of $1.31 (31.4% below fair value)
Industry Position: 61% above the Medical Devices & Instruments median (#314 of 691)
No single metric tells the full story. See the RPID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.
64GF Score
Get the complete analysis for RPID
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPID has been successfully added to your 
